Ron Smits

Ron Smits 0416-004Ron Smits 0416-004Associate Professor
Room: NA-1011
Fax: +31 10 7032793
m.j.m.smits@erasmusmc.nl

Professional Experience
Ron Smits studied Biomedical Sciences at the University of Leiden, The Netherlands (1985-1992). He performed his PhD study and Postdoctoral training at the Department of Human Genetics of the Leiden University. His thesis entitled "APC and cancer: It takes two to tango" was successfully defended in 2002 (cum laude). Beginning of 2003, he joined Genentech Inc., South San Francisco, CA, as a research scientist to establish and characterize spontaneous intestinal tumor models. Here, he also developed the research line to investigate the cross-talk between receptor tyrosine kinases and ß-catenin signaling in cancer for which he was awarded a Vidi (ZonMW) grant in 2004. This work was performed as assistant professor in the Department of Pathology of the Erasmus MC in Rotterdam, The Netherlands. Since January 2008, he is a staff member at the Department of Gastroenterology and Hepatology of the Erasmus MC, where he focuses on molecular mechanisms contributing to intestinal tumor formation and metastasis.

Selected references

  • Huisman SA, Bijman-Lagcher W, JN IJ, Smits R*, de Bruin RW*.
    Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice.
    Cell Cycle. 2015;14(14):2333-9.
    *equal contribution
  • Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, Kuo CJ, Camargo FD
    Restriction of intestinal stem cell expansion and the regenerative response by YAP.
    Nature. 2013 Jan 3;493(7430):106-10
  • Bakker ER, Das AM, Helvensteijn W, Franken PF, Swagemakers S, van der Valk MA, ten Hagen TL, Kuipers EJ, van Veelen W, Smits R.
    Wnt5a promotes human colon cancer cell migration and invasion but does not augment intestinal tumorigenesis in Apc1638N mice.
    Carcinogenesis. 2013 Nov;34(11):2629-38.
  • Bakker ER, Hoekstra E, Franken PF, Helvensteijn W, van Deurzen CH, van Veelen W, Kuipers EJ, Smits R.
    beta-Catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer.
    Oncogene. 2013 Sep 19;32(38):4579-85
  • Raghoebir L, Bakker ER, Mills JC, Swagemakers S, Kempen MB, Munck AB, Driegen S, Meijer D, Grosveld F, Tibboel D, Smits R*, Rottier RJ*.
    SOX2 redirects the developmental fate of the intestinal epithelium toward a premature gastric phenotype.
    J Mol Cell Biol. 2012 Dec;4(6):377-85.
    *equal contribution
  • van Veelen W, Le NH, Helvensteijn W, Blonden L, Theeuwes M, Bakker ER, Franken PF, van Gurp L, Meijlink F, van der Valk MA, Kuipers EJ, Fodde R, Smits R.
    beta-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis.
    Gut. 2011 Sep;60(9):1204-12
  • Albuquerque C, Bakker ER, van Veelen W, Smits R.
    Colorectal cancers choosing sides.
    Biochim Biophys Acta. 2011 Dec;1816(2):219-31
  • Roth S, Franken P, van Veelen W, Blonden L, Raghoebir L, Beverloo B, van Drunen E, Kuipers EJ, Rottier R, Fodde R, Smits R.
    Generation of a tightly regulated doxycycline-inducible model for studying mouse intestinal biology.
    Genesis. 2009 Jan;47(1):7-13
  • Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, Lage P, Slors FJ, Leitao CN, Fodde R, Smits R.
    The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade.
    Hum Mol Genet. 2002 Jun 15;11(13):1549-60
  • Fodde R, Smits R, Clevers H.
    APC, signal transduction and genetic instability in colorectal cancer.
    Nat Rev Cancer. 2001 Oct;1(1):55-67.